Immatics, Roche sign cancer vaccine and immunotherapy collaboration agreement

14-11-2013 Pharmaceutical Business ReviewComments (0)

Biotechnologyimmatics biotechnologiesRoche

Germany-based immatics biotechnologies and Switzerland-based F. Hoffmann-La Roche (Roche) have signed a strategic R&D collaboration agreement covering multiple cancer vaccines and immunotherapeutics. Pursuant to the terms of the agreement, ...

Read more on Pharmaceutical Business Review

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top